The primary objectives of the study are to evaluate the safety and tolerability, and pharmacokinetics (PK) of sotatercept over 24 weeks of treatment in children ≥1 to \<18 years of age with PAH World Health Organization (WHO) Group 1 on standard of care (SoC). There is no formal hypothesis.
Pulmonary Arterial Hypertension
The primary objectives of the study are to evaluate the safety and tolerability, and pharmacokinetics (PK) of sotatercept over 24 weeks of treatment in children ≥1 to \<18 years of age with PAH World Health Organization (WHO) Group 1 on standard of care (SoC). There is no formal hypothesis.
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
-
The Regents of the University of California - Los Angeles (UCLA Pediatrics) ( Site 1606), Los Angeles, California, United States, 90095
Stanford University School of Medicine ( Site 1603), Palo Alto, California, United States, 94304
UCSF Benioff Children's Hospital San Francisco ( Site 1611), San Francisco, California, United States, 94158
Children's Hospital Colorado ( Site 1609), Aurora, Colorado, United States, 80045
Children's National Medical Center ( Site 1600), Washington, District of Columbia, United States, 20010
Cincinnati Children's Hospital Medical Center ( Site 1602), Cincinnati, Ohio, United States, 45245
Children's Hospital of Philadelphia (CHOP) ( Site 1608), Philadelphia, Pennsylvania, United States, 19104
Monroe Carell Jr. Children's Hospital ( Site 1601), Nashville, Tennessee, United States, 37232
Seattle Children's Hospital ( Site 1605), Seattle, Washington, United States, 98105
Children's Wisconsin ( Site 1610), Milwaukee, Wisconsin, United States, 53226
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
1 Year to 17 Years
ALL
No
Merck Sharp & Dohme LLC,
Medical Director, STUDY_DIRECTOR, Merck Sharp & Dohme LLC
2028-09-21